A5087598270- Neuroblastoma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Cancer Immunotherapy and Biomarkers
- Cancer therapeutics and mechanisms
- Lymphoma Diagnosis and Treatment
- Pharmaceutical studies and practices
- Ethics and Legal Issues in Pediatric Healthcare
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Growth Hormone and Insulin-like Growth Factors
- Palliative Care and End-of-Life Issues
- Immune cells in cancer
- Chromatin Remodeling and Cancer
- Pancreatic and Hepatic Oncology Research
- Infrared Target Detection Methodologies
- Cancer Risks and Factors
- Advanced Measurement and Detection Methods
- Congenital Ear and Nasal Anomalies
- Chemotherapy-induced organ toxicity mitigation
- Archaeology and ancient environmental studies
- Neurofibromatosis and Schwannoma Cases
- Pituitary Gland Disorders and Treatments
Roche (Switzerland)
2016-2024
Great Ormond Street Hospital
2022
University College London
2022
Hopp Children's Cancer Center Heidelberg
2020
Emma Kinderziekenhuis
1992-2018
Amsterdam UMC Location University of Amsterdam
1996-2018
University of Amsterdam
1996-2018
University Medical Center Utrecht
2016
Committee on Publication Ethics
2007
Cancer Center Amsterdam
2005
Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors ROS1 non–small-cell lung cancer. We report an analysis STARTRK-NG trial, investigating recommended phase 2 dose (RP2D) activity entrectinib in pediatric patients including primary central nervous system tumors. (NCT02650401) 1/2 trial. Phase 1, dose-escalation oral, once-daily entrectinib, enrolled <22 with/without target...
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options less side effects. Since novel improved immunotherapies may fill this need, we dissect the immunoregulatory interactions in by single-cell RNA-sequencing of 24 tumors (10 pre- 14 post-chemotherapy, including 5 pairs) to identify strategies for optimizing immunotherapy efficacy. Neuroblastomas are infiltrated natural killer (NK), T B cells, immunosuppressive myeloid...
Purpose To evaluate the prevalence of, and risk factors for, early endocrine disorders in childhood brain tumor survivors (CBTS). Patients Methods This nationwide study cohort consisted of 718 CBTS who were diagnosed between 2002 2012, survived ≥ 2 years after diagnosis. with craniopharyngeoma or a pituitary gland excluded. Results all investigations, which performed at diagnosis during follow-up, collected from patient charts. Multivariable logistic regression was used to associations...
The third multistakeholder Paediatric Strategy Forum organised by ACCELERATE and the European Medicines Agency focused on immune checkpoint inhibitors for use in combination therapy children adolescents. As inhibitors, both as monotherapy combinations have shown impressive success some adult malignancies early phase trials of single agent now been completed, it seemed an appropriate time to consider opportunities paediatric studies used combination. Among patients, clinical demonstrated a...
PURPOSE Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens the addition of antiangiogenic agent bevacizumab (B). MATERIALS AND METHODS Patients age 1-21 years RR-HRNB adequate organ function performance status were randomly assigned in a 3 × 2 factorial design to temozolomide (T), irinotecan-temozolomide (IT), or topotecan-temozolomide (TTo)...
Clinical morphology has proved essential for the successful delineation of hundreds syndromes and as a powerful instrument detecting (candidate) genes (Gorlin et al. [2001]; Syndromes Head Neck; Oxford: Oxford University Press. 1 p]. The major approach to reach this been careful clinical evaluations patients, focused on congenital anomalies. A similar physical examination performed in who have treated childhood cancer, may allow detection concurrent patterns anomalies provide clues causative...
Background Pediatric oncology patients with tunneled central venous catheters (CVCs) are at increased risk to develop thromboembolic events (VTEs), but the true prevalence of (a)symptomatic VTE is unknown. Aim this study was evaluate in pediatric CVCs. Procedure All were included Aristocaths study: a randomized controlled multicenter trial investigating prophylactic effect 70% ethanol locks on CVC-associated bloodstream infections (CABSIs) eligible for study. We assessed following outcomes:...
Although colorectal adenomas serve as prime target for cancer (CRC) surveillance in other high-risk groups, data on adenoma risk after childhood are lacking. We evaluated the of histologically confirmed among survivors. A secondary aim was to assess CRC risk.The DCOG-LATER cohort study includes five-year Dutch survivors and a sibling comparison group (n = 883). Colorectal tumors were identified from population-based Pathology Registry (PALGA). calculated cumulative incidences adenomas/CRCs...
Previous studies have reported changes in the body mass index (BMI) with time childhood cancer survivors (CCSs) during follow-up. The limitations of these include that they described only a subgroup or used questionnaires self-reported heights and weights. goal this study was to examine BMI large cohort long-term CCSs relate at diagnosis, age, sex, tumor type, treatment, endocrine defects.All patients treated for Emma Children's Hospital/Academic Medical Center between 1966 1996 who had...
Abstract We monitored renal tubular function in 18 neuroblastoma patients treated with chemotherapeutic regimens containing Ifosfamide and platinates. The total IFO dose ranged from 30 to 48 g/m 2 . After each course at regular intervals during follow‐up 24 hour urinary excretion of aminoacids, qualitative protein glucose, reabsorption phosphate, serum pH, liver enzyme (SGOT SGPT) were measured. ratio α‐amino‐Nitrogen/total‐Nitrogen (normal <2.5%) the pattern used quantify aminoaciduria...
Morbidity and mortality from primary varicella-zoster virus (VZV) infection is increased in immunocompromised children. Vaccination of VZV-seronegative cancer patients with live-attenuated varicella vaccine safe when chemotherapy interrupted. However, VZV vaccination without interruption would be preferable. To vaccinate pediatric oncology interrupting their chemotherapy. We performed a single-center prospective cohort study. Thirty-one either hematological malignancy (n = 24) or solid tumor...
Childhood cancer is still a leading cause of death around the world. To improve outcomes, there an urgent need for tailored treatment. The systematic evaluation existing preclinical data can provide overview what known and identify gaps in current knowledge. Here, we applied target actionability review (TAR) methodology to assess strength weaknesses available scientific literature on CDK4/6 as therapeutic paediatric solid brain tumours by structured critical appraisal.Using relevant search...
Abstract Childhood cancer survivors ( CCS ) experience higher hospitalization rates compared to the general population for neoplasms, circulatory diseases, endocrine/nutritional/metabolic diseases and eye disorders. We studied trends in associated patient treatment‐specific risk factors diagnosis subgroups among these four diseases. performed medical record linkage of a ≥5‐year cohort with national registers, obtained random reference sample matched on age, gender calendar year per . For...